VSIR and neoplasm: In contrast, treatment with an anti-VISTA monoclonal antibody (mAb) resulted in a reduction of tumor-infiltrating MDSCs accompanied by an increase of tumor-infiltrating CD4+ and CD8+ T cells (16, 22).